Anthrogenesis Corporation

Celularity Inc.

Antrhogenesis Corporation

Clarity Acquisition Ii LLC

Eric Law

Robert J Hariri

Stewart Abbot

Vladimir Jankovic

Jennifer Paredes

James W Edinger

Xiaokui Zhang

Jia-Lun Wang

Vanessa R Voskinarian-Berse

Lin Kang

Kristen S Labazzo

Aleksandar Francki

Aleksandr Kaplunovsky

Andrew L Zeitlin

Mohammad A Heidaran

Ajai Pal

Neerav D Padliya

Wolfgang Hofgartner

Stephen Jasko

Bhavani Stout

Kathy Karasiewicz-Mendez

Ivana Djuretic

Allan Reduta

Aleksander Francki

Andrew Morschauser

Vanessa Voskinarian-berse

Kathy E Karasiewicz-mendez

Vanessa Voskinarian-Berse

Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.

Placenta-derived adherent cell exosomes and uses thereof

Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.

Natural killer cells from placenta

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

Methods of generating natural killer cells

Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.

Angiogenesis using placental stem cells

Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.

Amnion derived adherent cells

Growing community of inventors

East Brunswick, NJ, United States of America

Eric Law